While targeting T cells has proven to be a technically successful treatment protocol for most cancer immunotherapies, only a fraction of cancer patients respond to these interventions. Of late there has been a surge of interest in investigating the relatively underexplored innate immune system as a possible tool for therapeutic intervention. Innate immune effector cells, including natural killer cells, macrophages, and dendritic cells, have been shown to interact with cancers and inhibit their progression. Dissecting the molecular details of these interactions will aid in identifying cancer-derived intrinsic factors that can be exploited to be develop effective immunotherapy regimens. Our speakers will provide examples of how innate immunity pathways are involved in fighting cancer, and how these pathways might be co-opted to generate new treatments.
During the webinar, viewers will:
- Learn how dendritic cells maintain a local antitumor immune response within the tumor microenvironment
- Gain an understanding of how therapeutic interventions targeting dendritic cells can promote tumor immunity and enhance the efficacy of cancer therapy
- Hear how inflammatory pathways, commonly upregulated in human malignancies, represent major determinants of tumor fate
- Have their questions answered during the live broadcast!
This webinar will last for approximately 60 minutes.
You can also view Part 1 of this series.